JP2020505475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505475A5 JP2020505475A5 JP2019562229A JP2019562229A JP2020505475A5 JP 2020505475 A5 JP2020505475 A5 JP 2020505475A5 JP 2019562229 A JP2019562229 A JP 2019562229A JP 2019562229 A JP2019562229 A JP 2019562229A JP 2020505475 A5 JP2020505475 A5 JP 2020505475A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- item
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022181719A JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453413P | 2017-02-01 | 2017-02-01 | |
| US62/453,413 | 2017-02-01 | ||
| PCT/US2018/016148 WO2018144542A1 (en) | 2017-02-01 | 2018-01-31 | TGFβ AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022181719A Division JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505475A JP2020505475A (ja) | 2020-02-20 |
| JP2020505475A5 true JP2020505475A5 (https=) | 2021-03-11 |
| JP7246617B2 JP7246617B2 (ja) | 2023-03-28 |
Family
ID=63041217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562229A Active JP7246617B2 (ja) | 2017-02-01 | 2018-01-31 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
| JP2022181719A Pending JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022181719A Pending JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200306340A1 (https=) |
| EP (1) | EP3576773B1 (https=) |
| JP (2) | JP7246617B2 (https=) |
| KR (1) | KR20190115037A (https=) |
| CN (1) | CN110494155A (https=) |
| AU (1) | AU2018214979A1 (https=) |
| CA (1) | CA3051696A1 (https=) |
| WO (1) | WO2018144542A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CA3103427A1 (en) * | 2018-06-15 | 2019-12-19 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| CN116390940A (zh) * | 2020-09-23 | 2023-07-04 | 海正生物制药有限公司 | Tgfbr2-ecd突变体及包含其的融合蛋白与应用 |
| CA3196443A1 (en) * | 2020-11-04 | 2022-05-12 | Hq Han | Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| CN117721131A (zh) * | 2023-12-19 | 2024-03-19 | 吉林大学 | 一种重组骨形态发生蛋白突变体的制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1486560A3 (en) * | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US8293252B2 (en) * | 2006-12-20 | 2012-10-23 | Novarx Corporation | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| MX2009008222A (es) * | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
| TW201803890A (zh) * | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EA018221B1 (ru) * | 2007-02-09 | 2013-06-28 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
| CN101780272B (zh) * | 2009-12-24 | 2012-01-25 | 湖南农业大学 | 一种含有TGF β1自体疫苗制剂的应用 |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CN103732623B (zh) * | 2011-06-03 | 2017-09-29 | 佐马技术有限公司 | 对TGF‑β具有特异性的抗体 |
| MA41920B1 (fr) * | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| US10358476B2 (en) * | 2015-04-06 | 2019-07-23 | Acceleron Pharma Inc. | Single arm type I and type II receptor fusion proteins and uses thereof |
| US10723793B2 (en) * | 2015-06-12 | 2020-07-28 | Ludwig Institute For Cancer Research, Ltd. | TGF-β3 specific antibodies and methods and uses thereof |
| US20170240639A1 (en) * | 2016-02-22 | 2017-08-24 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
-
2018
- 2018-01-31 EP EP18747362.4A patent/EP3576773B1/en active Active
- 2018-01-31 US US16/482,869 patent/US20200306340A1/en not_active Abandoned
- 2018-01-31 JP JP2019562229A patent/JP7246617B2/ja active Active
- 2018-01-31 CA CA3051696A patent/CA3051696A1/en active Pending
- 2018-01-31 CN CN201880023489.0A patent/CN110494155A/zh active Pending
- 2018-01-31 WO PCT/US2018/016148 patent/WO2018144542A1/en not_active Ceased
- 2018-01-31 KR KR1020197025689A patent/KR20190115037A/ko not_active Ceased
- 2018-01-31 AU AU2018214979A patent/AU2018214979A1/en not_active Abandoned
-
2022
- 2022-11-14 JP JP2022181719A patent/JP2023012552A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505475A5 (https=) | ||
| JP7818838B2 (ja) | 二重特異性抗体およびその適用 | |
| CN102099374B (zh) | 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 | |
| CN111423512B (zh) | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 | |
| WO2019062642A1 (zh) | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 | |
| JP2018503380A5 (https=) | ||
| JP6519090B2 (ja) | 血管内皮成長因子融合タンパク質 | |
| JP2017101068A5 (https=) | ||
| JP2019506863A (ja) | Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質 | |
| JP2013507926A (ja) | ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用 | |
| CN101652387A (zh) | Alk1受体和配体拮抗剂及其用途 | |
| JP2011504176A (ja) | マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法 | |
| JP2019058160A (ja) | ヒトｐ１８５及び血管内皮増殖因子の両方を標的とする抗体及びその適用 | |
| JP2018501211A5 (https=) | ||
| JP2022517920A5 (https=) | ||
| CN102884084A (zh) | 抗her2抗体及组合物 | |
| JP2022501361A5 (https=) | ||
| JP2021527425A5 (https=) | ||
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| JP2023531672A (ja) | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 | |
| CN114044827A (zh) | 低adcc/cdc功能性单抗及其制备方法与应用 | |
| CN114616251B (zh) | 靶向PD-1和TGFβ的重组蛋白 | |
| JP6887944B2 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| AU2023336948A1 (en) | Pharmaceutical composition and use thereof |